Cargando…
Complementary Therapy to Target LDL Cholesterol: The Role of the Ezetimibe/Simvastatin Combination
Cardiovascular (CV) disease remains the number 1 cause of death in the USA. Nonetheless, there has been a decline in the age-adjusted death rate for coronary heart disease (CHD) which may be due to more aggressive treatment guidelines for treating CV risk factors, such as hypertension, diabetes, and...
Autores principales: | Neal, Ryan C, Jones, Peter H |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993974/ https://www.ncbi.nlm.nih.gov/pubmed/17319467 |
Ejemplares similares
-
Reaching target LDL cholesterol has become more affordable with launch of ezetimibe/simvastatin combination in South Africa
Publicado: (2010) -
Combination therapy in cholesterol reduction: focus on ezetimibe and statins
por: Grigore, Liliana, et al.
Publicado: (2008) -
Ezetimibe and Simvastatin Reduce Cholesterol Levels in Zebrafish Larvae Fed a High-Cholesterol Diet
por: Baek, Ji Sun, et al.
Publicado: (2012) -
Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients
por: Ahmed, Osman, et al.
Publicado: (2018) -
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
por: Baigent, Colin, et al.
Publicado: (2011)